Towards achieving remission in the treatment of depression
Open accessThe DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
The burden of depressive illness constitutes a major public health issue. Despite real progress and better tolerance of new antidepressant medications, a significant number of depressed patients still suffer from rather severe residual depressive symptoms.This relative lack of efficacy clearly interferes with their psychosocial functioning and their quality of life. In addition, it is now well-recognized that the failure to reach full clinical remission after antidepressant treatment involves a high risk of relapse or recurrence in patients suffering from major depression, This paper reviews the concept of remission across different definitions, and the potential risk factors associated with the failure to reach clinical remission. The identification of specific residual symptoms in nonremitted patients is also of great importance, in order to assess the predictive value of those symptoms in relation to relapse and recurrence. Some methodological issues are also discussed, as well as various therapeutic strategies aimed at relieving residual depressive symptoms. Clinical remission remains a gold standard and a primary objective of modern antidepressant therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Frank, E. (1991) · Archives of General Psychiatry · doi:10.1001/archpsyc.1991.01810330075011 · Cited by 1,959 · cited 1×
“There is no general consensus about the length of time the depressed patient in remission should remain in remission, but, according to most experts, this period of remission is expected to last between 4 and 6 months to be of clinical relevance for the patient.(10) S t a t e o f t h e a r t”
BackgroundRelapse prevention with antidepressant drug treatment in depressive disorders: a systematic review
Geddes, J. R., Carney, S. M., Davies, C., Furukawa, T. A., Kupfer, D. J., Frank, E., & Goodwin, G. M. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12599-8 · Cited by 945
Residual symptoms after partial remission: an important outcome in depression
Paykel, E. S., Ramana, R., Cooper, Z., Hayhurst, H., Kerr, J., & Barocka, A. (1995) · Psychological Medicine · doi:10.1017/s0033291700033146 · Cited by 791 · cited 3×
“Among the most frequent residual symptoms targeted, one finds anxiety symptoms, sleep disturbances, depressed mood, work difficulties, fatigue, and lack of interest.(15,24,25) The rather high rate of manifestation of residual symptoms observed in nonremitted depressed patients justifies the need for research into vari…”
BackgroundJudd, L. L., Akiskal, H. S., Maser, J. D., Zeller, P. J., Endicott, J., Coryell, W., Paulus, M. P., Kunovac, J. L., Leon, A. C., Mueller, T. I., et al. (1998) · Archives of General Psychiatry · doi:10.1001/archpsyc.55.8.694 · Cited by 775
Report by the ACNP Task Force on Response and Remission in Major Depressive Disorder
Rush, A. J., Kraemer, H. C., Sackeim, H. A., Fava, M., Trivedi, M. H., Frank, E., Ninan, P. T., Thase, M. E., Gelenberg, A. J., Kupfer, D. J., et al. (2006) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301131 · Cited by 707 · cited 2×
“The ACNP Task Force also reviewed the literature on potential associated factors which may influence the remission, the time of remission and the stability of the remission.(6) These factors include among others the type of treatment, the dose, the duration of treatment, baseline severity of depressive symptoms, the s…”
BackgroundJudd, L. L., Akiskal, H. S., Maser, J. D., Zeller, P. J., Endicott, J., Coryell, W., Paulus, M. P., Kunovac, J. L., Leon, A. C., Mueller, T. I., et al. (1998) · Journal of Affective Disorders · doi:10.1016/s0165-0327(98)00138-4 · Cited by 590
Residual symptoms in depressed patients who respond acutely to fluoxetine
Nierenberg, A. A., Keefe, B. R., Leslie, V. C., Alpert, J. E., Pava, J. A., Worthington, J. J., Rosenbaum, J. F., & Fava, M. (1999) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v60n0403 · Cited by 470 · cited 1×
“Among the most frequent residual symptoms targeted, one finds anxiety symptoms, sleep disturbances, depressed mood, work difficulties, fatigue, and lack of interest.(15,24,25) The rather high rate of manifestation of residual symptoms observed in nonremitted depressed patients justifies the need for research into vari…”
BackgroundJudd, L. L., Paulus, M. J., Schettler, P. J., Akiskal, H. S., Endicott, J., Leon, A. C., Maser, J. D., Mueller, T., Solomon, D. A., & Keller, M. B. (2000) · American Journal of Psychiatry · doi:10.1176/appi.ajp.157.9.1501 · Cited by 458
(1992) · American Journal of Psychiatry · doi:10.1176/ajp.149.8.1046 · Cited by 252
Hirschfeld, R. M. A., Dunner, D. L., Keitner, G., Klein, D. N., Koran, L. M., Kornstein, S. G., Markowitz, J. C., Miller, I., Nemeroff, C. B., Ninan, P. T., et al. (2002) · Biological Psychiatry · doi:10.1016/s0006-3223(01)01291-4 · Cited by 231
Cited by
Akhondzadeh, S., Jafari, S., Raisi, F., Nasehi, A. A., Ghoreishi, A., Salehi, B., Mohebbi-Rasa, S., Raznahan, M., & Kamalipour, A. (2009) · Depression and Anxiety · doi:10.1002/da.20589 · Cited by 397
Kopschina Feltes, P., Doorduin, J., Klein, H. C., Juárez-Orozco, L. E., Dierckx, R. A., Moriguchi-Jeckel, C. M., & de Vries, E. F. (2017) · Journal of Psychopharmacology · doi:10.1177/0269881117711708 · Cited by 279
“For those patients who fail to respond to the initial antidepressant therapy, alternative treatment approaches are switching medication, augmentation or combination therapies (Mendlewicz, 2008).”
BackgroundEsketamine Nasal Spray versus Quetiapine for Treatment-Resistant Depression
Reif, A., Bitter, I., Buyze, J., Cebulla, K., Frey, R., Fu, D.-J., Ito, T., Kambarov, Y., Llorca, P.-M., Oliveira-Maia, A. J., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2304145 · Cited by 222
Faridhosseini, F., Sadeghi, R., Farid, L., & Pourgholami, M. (2014) · Human Psychopharmacology: Clinical and Experimental · doi:10.1002/hup.2401 · Cited by 89
The antidepressant mechanism of action of vagus nerve stimulation: Evidence from preclinical studies
Grimonprez, A., Raedt, R., Baeken, C., Boon, P., & Vonck, K. (2015) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2015.06.019 · Cited by 81
Metadata
- Authors
- Mendlewicz, J.
- Venue
- Dialogues in Clinical Neuroscience
- Publisher
- Informa UK Limited
- Published
- 2008-12-31
- Volume
- 10
- Issue
- 4
- Pages
- 371-375
- ISSN
- 1294-8322 (ISSN-L)
- 1958-5969
- OpenAlex
- W190378794
- Cited by
- 52
- References
- 12
- FWCI
- 1.03
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Towards achieving remission in the treatment of depression. https://app.cochat.ai/papers/10.31887/dcns.2008.10.4/jmendlewicz
- The paper
- Mendlewicz, J. (2008). Towards achieving remission in the treatment of depression. Dialogues in Clinical Neuroscience. https://doi.org/10.31887/dcns.2008.10.4/jmendlewicz
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.